What question did this study set out to answer?

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.

synapse

⌘+K

synapse

⌘+K

April 15, 2026Open Access

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Key Points

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.
Conducted a retrospective multi-center cohort study
Analyzed treatment data of Taiwanese PDAC patients
Assessed efficacy and tolerability associated with various initial dose intensities.
An initial relative dose intensity of 70-90% for irinotecan and oxaliplatin was optimal.
Patients experienced improved efficacy and tolerability at this dose range.

Abstract

The initial RDI of 70-90% for irinotecan and oxaliplatin may optimize both efficacy and tolerability in Taiwanese PDAC patients treated with FOLFIRINOX.

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Key Points

Abstract

Cite This Study

Also Consider

Also Consider